These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 24997410)

  • 1. Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs-a fenofibrate case example.
    Berthelsen R; Sjögren E; Jacobsen J; Kristensen J; Holm R; Abrahamsson B; Müllertz A
    Int J Pharm; 2014 Oct; 473(1-2):356-65. PubMed ID: 24997410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
    O'Shea JP; Faisal W; Ruane-O'Hora T; Devine KJ; Kostewicz ES; O'Driscoll CM; Griffin BT
    Eur J Pharm Biopharm; 2015 Oct; 96():207-16. PubMed ID: 26215636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles.
    Juenemann D; Jantratid E; Wagner C; Reppas C; Vertzoni M; Dressman JB
    Eur J Pharm Biopharm; 2011 Feb; 77(2):257-64. PubMed ID: 21074611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.
    Buch P; Langguth P; Kataoka M; Yamashita S
    J Pharm Sci; 2009 Jun; 98(6):2001-9. PubMed ID: 18855916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.
    Do TT; Van Speybroeck M; Mols R; Annaert P; Martens J; Van Humbeeck J; Vermant J; Augustijns P; Van den Mooter G
    Int J Pharm; 2011 Jul; 414(1-2):118-24. PubMed ID: 21596119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
    Shono Y; Jantratid E; Dressman JB
    Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IVIVR in oral absorption for fenofibrate immediate release tablets using dissolution and dissolution permeation methods.
    Buch P; Holm P; Thomassen JQ; Scherer D; Kataoka M; Yamashita S; Langguth P
    Pharmazie; 2010 Oct; 65(10):723-8. PubMed ID: 21105572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for the poorly soluble drug fenofibrate.
    Cho YD; Park YJ
    Arch Pharm Res; 2014 Feb; 37(2):193-203. PubMed ID: 23754165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
    Borkar N; Xia D; Holm R; Gan Y; Müllertz A; Yang M; Mu H
    Eur J Pharm Sci; 2014 Jan; 51():204-10. PubMed ID: 24134899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential.
    Hens B; Brouwers J; Corsetti M; Augustijns P
    Eur J Pharm Sci; 2015 Sep; 77():40-7. PubMed ID: 26004010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of a PGSS (particles from gas saturated solutions) process for a fenofibrate lipid-based solid dispersion formulation.
    Pestieau A; Krier F; Lebrun P; Brouwers A; Streel B; Evrard B
    Int J Pharm; 2015 May; 485(1-2):295-305. PubMed ID: 25796121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate.
    Jia Z; Lin P; Xiang Y; Wang X; Wang J; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2011 Sep; 79(1):126-34. PubMed ID: 21658449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
    McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
    J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability.
    Zhang L; Chai G; Zeng X; He H; Xu H; Tang X
    Drug Dev Ind Pharm; 2010 Sep; 36(9):1054-63. PubMed ID: 20818965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability.
    Ige PP; Baria RK; Gattani SG
    Colloids Surf B Biointerfaces; 2013 Aug; 108():366-73. PubMed ID: 23602990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of fenofibrate microemulsion for improved bioavailability.
    Hu L; Wu H; Niu F; Yan C; Yang X; Jia Y
    Int J Pharm; 2011 Nov; 420(2):251-5. PubMed ID: 21907776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.